Edward Garon, MD

Edward B. Garon, MD, MS, discusses data from the phase 3 CANOPY-A study and what they mean for the future of canakinumab for patients with non–small cell lung cancer.

Edward B. Garon, MD, MS, discusses the mechanism of action of canakinumab.

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.

Garon says the likely place to start when looking into combination therapies are cytotoxic chemotherapy and tyrosine kinase inhibitors, given these treatments are currently approved in lung cancer.